Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Multiomics-guided ex vivo drug sensitivity testing in Relapsed/Refractory Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

SCSikander ChohanYSYang ShiJYJay Yang

Discussion

Loading...

Member takes

Overview

Integration of multiomics and ex vivo testing unveils biomarkers for anti-cancer drug response in R/R AML.

Key Points

  • This research aims to integrate multiomics data with ex vivo drug sensitivity testing to find predictive biological signatures for therapeutic responses in R/R AML.
  • Reviewed clinical and genomic characteristics of 16 R/R AML patients
  • Performed ex vivo high-throughput drug sensitivity testing on 64 anti-cancer drugs
  • Used whole exome and transcriptome sequencing, including micro RNA sequencing
  • 10 out of 16 patient samples were included for analysis due to sufficient viability
  • Median patient age was 58, with significant mutations like DNMT3A, FLT3, and IDH2 identified
  • 22 drugs were found to correlate with patient responses, demonstrating potential biomarker signatures

Cite This Study

Chohan et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da1fhttps://doi.org/10.1182/blood-2025-3496
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ex vivo drug sensitivity testing in Korean AML patients: Integration of functional and genomic profiles for predicting clinical response and survival2025
  2. 2A rapid gene expression profiler predicts tumor responsiveness and patient outcome for standard-of-care therapies in acute myeloid leukemia2025 · 1 citations
  3. 3P06 | FROM BENCH TO BEDSIDE: DRUG SENSITIVITY PROFILING TO OPTIMIZE THERAPY IN RELAPSED MULTIPLE MYELOMA2026
  4. 4Integrative analysis of drug response and clinical outcome in acute myeloid leukemia2022 · 400 citations
  5. 5The transition from myelodysplastic neoplasm to secondary acute myeloid leukemia is revealed by molecular analysis, while functional drug screening demonstrates novel sensitivity patterns with clinical implication2025